The Medicines Patent Pool’s work depends on partnerships with stakeholders in the field of HIV, hepatitis C and tuberculosis, and its partnerships with patent holding companies are critical to its success.
The MPP has signed licensing agreements with AbbVie, Bristol-Myers Squibb, Gilead Sciences, the Johns Hopkins University, MSD (Merck & Co in the USA and Canada), Pharco Pharmaceuticals, Roche, ViiV Healthcare [a joint venture of GlaxoSmithKline, Pfizer and Shionogi], the University of Liverpool and the US National Institutes of Health.
The MPP released its 2017 prioritization report in February 2017 selecting five HIV and two hepatitis C compounds for potential licensing agreements. In April 2017, the foundation announced a licence for one targeted hepatitis C compound, ravidasvir. The MPP also entered into negotiations with Gilead Sciences for HIV medicine bictegravir.
The Medicines Patent Pool has also sublicensed to generic manufacturers and product developers, who are already beginning to produce and supply medicines at a lower cost. As of May 2017, the MPP had signed sub-licensing agreements with sixteen generic manufacturers and product developers: Aurobindo Pharma Limited, Beximco, Cipla, Desano, Emcure Pharmaceuticals, Hetero Labs, Huahai Pharmaceutical, Laurus Labs, Lupin, Micro Labs, Mylan, Natco, Sandoz, Strides Arcolab, TB Alliance and Zydus Cadila.
The MPP looks forward to continuing dialogue with all relevant patent holders and eligible generic manufacturers and product development partnerships to increase access to medicines for people living in developing countries.
Patent Holder Engagement